Early-Stage Technologies In Brief
This article was originally published in The Gray Sheet
Executive Summary
Biowave DeepTreat: Initial 510(k) clearance is likely in second quarter of 2004 for pain-blocking technology, Norwalk, Conn. firm tells potential investors during recent Medtech Insight conference in Boston. The product is similar to implanted neuromodulation devices, but can be done in a physician's office at a lower cost, according to Biowave. In clinical studies of the device, which incorporates a disposable, percutaneous electrode array with 3,600 microneedles that deliver an electric field signal into deep tissue, patients report an average 80% reduction in pain at one hour post-treatment. DeepTreat thus reduces the need for painkillers, the company says. The product is reimbursed at $125-$320 per treatment, and a CPT code is expected as early as Q1 2004. Biowave is seeking $7 mil. to complete development...
You may also be interested in...
VMBC’s Vasclip
U.S. launch of less-invasive vasectomy alternative is announced April 30. The device received 510(k) clearance in August 2002. About the size of a grain of rice, the polymeric clip locks around the vas deferens, causing sterility. No cutting, suturing or cauterizing of the vessel is required, according to the Roseville, Minn. company. Over 4 mil. vasectomies are performed worldwide every year, including 500,000 in the U.S...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.